- Home
- MAC vs AXNX Comparison
MAC vs AXNX Comparison
Compare MAC & AXNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAC
- AXNX
- Stock Information
- Founded
- MAC 1964
- AXNX 2012
- Country
- MAC United States
- AXNX United States
- Employees
- MAC N/A
- AXNX N/A
- Industry
- MAC Real Estate Investment Trusts
- AXNX Medical/Dental Instruments
- Sector
- MAC Real Estate
- AXNX Health Care
- Exchange
- MAC Nasdaq
- AXNX Nasdaq
- Market Cap
- MAC 4.4B
- AXNX 3.6B
- IPO Year
- MAC 1994
- AXNX N/A
- Fundamental
- Price
- MAC $19.58
- AXNX N/A
- Analyst Decision
- MAC Hold
- AXNX Hold
- Analyst Count
- MAC 9
- AXNX 8
- Target Price
- MAC $16.40
- AXNX $71.00
- AVG Volume (30 Days)
- MAC 1.6M
- AXNX 571.3K
- Earning Date
- MAC 11-06-2024
- AXNX 11-07-2024
- Dividend Yield
- MAC 3.45%
- AXNX N/A
- EPS Growth
- MAC N/A
- AXNX N/A
- EPS
- MAC 0.36
- AXNX N/A
- Revenue
- MAC $788,288,000.00
- AXNX $431,902,000.00
- Revenue This Year
- MAC N/A
- AXNX $25.35
- Revenue Next Year
- MAC $3.53
- AXNX $19.92
- P/E Ratio
- MAC $54.93
- AXNX N/A
- Revenue Growth
- MAC N/A
- AXNX 26.08
- 52 Week Low
- MAC $10.75
- AXNX $55.09
- 52 Week High
- MAC $20.40
- AXNX $71.05
- Technical
- Relative Strength Index (RSI)
- MAC 60.28
- AXNX 1.26
- Support Level
- MAC $18.98
- AXNX $70.37
- Resistance Level
- MAC $19.66
- AXNX $71.05
- Average True Range (ATR)
- MAC 0.68
- AXNX 0.15
- MACD
- MAC -0.02
- AXNX -8.31
- Stochastic Oscillator
- MAC 64.44
- AXNX 0.00
About MAC Macerich Company (The)
The Macerich Company invests in premium mall assets. The company owns 28 regional malls in its consolidated portfolio and 14 regional malls in its unconsolidated portfolio along with three power centers and seven other real estate assets. The company's total portfolio has 45.5 million square feet of gross leasable area and averaged $836 sales per square foot over the 12 months ended in December 2023.
About AXNX Axonics Inc.
Axonics Inc is a United States-based medical technology company. It focuses on developing and commercializing novel products for adults with bladder and bowel dysfunction, that include implantable SNM systems to treat urinary urge incontinence and urinary urgency frequency (UUF); a urethral bulking agent (Bulkamid) to treat female stress urinary incontinence. SNM therapy is predominantly used to treat patients with overactive bladder, fecal incontinence, and urinary retention. Geographically, the company generates majority of its revenue from United States and rest from International markets.